CEO Executive AssistantMedical and scientific affairs sits at the heart of pharmaceutical credibility. It is where the science meets the market, where clinical evidence becomes clinical practice, and where company integrity is either built or eroded. For pharma CEOs who came up through science, medicine, or research, this function often feels like home territory. That familiarity makes it one of the hardest functions to delegate cleanly.
But delegation here is not optional if you intend to lead at scale. This article gives you a practical approach to delegating medical and scientific affairs while protecting the scientific integrity and strategic alignment that make the function valuable.
Why Medical Affairs Is a Delegation Trap for Science-Trained CEOs
Pharma CEOs with MD or PhD backgrounds bring something genuinely valuable to their role: the ability to speak credibly about science, to challenge clinical assumptions, and to engage key opinion leaders as peers. These are real competitive advantages.
The delegation problem begins when that scientific credibility becomes a reason for the CEO to stay operationally involved in medical affairs. You start reviewing publication plans personally. You attend advisory board meetings that your Chief Medical Officer should be running. You weigh in on medical information response letters. You become the informal scientific authority that your medical affairs team defers to rather than the executive leader who holds the function accountable at the organizational level.
The outcome is predictable: your medical affairs organization develops a dependency on your judgment, slows down when you are unavailable, and never fully develops the independent scientific leadership capacity it needs.
Your scientific background is most valuable when it sharpens your strategic questions and your ability to evaluate your medical affairs leaders. It is least valuable when it keeps you in operational scientific decisions your team should own.
Defining the Boundary: What the CEO Owns in Medical Affairs
Clarity starts with defining what genuinely belongs at CEO level in medical affairs.
You own the strategic positioning of science. How the company’s scientific evidence base differentiates the portfolio in the marketplace, how the company engages with the scientific community, and how medical affairs resources are allocated across the pipeline are CEO-level questions. You resolve them in partnership with your CMO, not by yourself.
You own the Chief Medical Officer relationship. This is a critical hire and a critical ongoing accountability. Your CMO must be someone you trust deeply with scientific judgment, stakeholder engagement, and organizational leadership. If you do not trust your CMO at this level, the delegation structure will not hold.
You own cross-functional strategic decisions where medical affairs intersects with commercial, regulatory, or corporate strategy. When the question is whether to pursue a new indication that requires medical affairs investment but also affects commercial priorities and regulatory timelines, that is a CEO conversation.
You own decisions about external scientific relationships at the most senior level. Relationships with scientific advisors who are also board candidates, academic medical centers that are strategic partners, and government scientific agencies that affect the operating environment. These relationships require the CEO chair.
Everything below these thresholds belongs in the medical and scientific affairs organization.
Building the Medical Affairs Delegation Structure
A functional delegation structure for medical affairs runs through the Chief Medical Officer or Head of Medical Affairs. If your organization separates the CMO role from the Head of Medical Affairs, you need clear coordination between these two leaders and clarity about who owns what.
Here is how the delegation structure maps across the primary medical affairs functions.
Medical Science Liaisons
Medical science liaisons are the field-facing scientific experts who engage healthcare providers, researchers, and institutional decision-makers. Their day-to-day activity, including call planning, scientific exchange content, and HCP engagement priorities, belongs in the MSL leadership organization. The Head of Medical Affairs or a VP of Field Medical sets direction, monitors performance, and manages escalations. You should not be in the weeds of MSL activity. Your touchpoint is aggregate performance data at the quarterly business review.
Publication Strategy and Medical Writing
Your publication strategy determines how the company’s clinical evidence reaches the scientific community. This is a function with significant scientific integrity implications. The owner is your CMO or Head of Medical Affairs, with a publication steering committee that includes medical affairs, clinical development, and legal representation.
The CEO’s role is to establish the principles governing publication strategy: commitment to transparency, timely publication of all pivotal trial results, and clear governance for sponsored research disclosure. You do not review individual publication plans or approve individual manuscript submissions unless the publication involves data that could affect public guidance or create significant regulatory exposure.
Advisory Boards and Key Opinion Leader Engagement
Advisory boards are critical for gathering scientific input, building KOL relationships, and ensuring medical affairs activities reflect current clinical practice. Your CMO or Head of Medical Affairs organizes and runs these boards. You may attend as a participant or observer for the most strategically significant boards, particularly for a flagship asset or a new therapeutic area entry.
Be deliberate about which advisory boards genuinely require CEO presence. If you attend too many, the function becomes performative. If you attend the right ones, you demonstrate commitment to scientific rigor and build relationships with the scientific leaders who matter most to the company.
Medical Information and Pharmacovigilance
Medical information response systems and pharmacovigilance are regulatory requirements with significant compliance implications. These functions belong entirely within the medical affairs and regulatory organization. You engage when a pharmacovigilance signal reaches the threshold of potential labeling change or significant patient safety action. Routine safety reporting, aggregate case review, and medical information operations are managed by your CMO and their team.
Health Economics and Outcomes Research
HEOR generates the economic evidence that supports payer negotiations and health technology assessment submissions. It sits at the intersection of medical affairs and commercial. Your Head of HEOR typically reports through medical affairs or market access. The CEO’s touchpoint is the strategic HEOR plan and its connection to market access priorities for major assets. Execution belongs in the function.
Pharma clinical trials requires a parallel delegation logic: the CEO sets portfolio-level clinical priorities, and the operational execution lives within the development organization.
The CMO Relationship: Making Delegation Work
Your Chief Medical Officer is the linchpin of your medical affairs delegation structure. Investing in this relationship is the highest-leverage thing you can do to make delegation sustainable.
Establish a structured weekly or biweekly one-on-one with your CMO. Use it for three purposes: strategic alignment on medical affairs priorities, early warning on emerging scientific or safety issues, and CMO professional development and support. Your CMO should feel genuinely supported and empowered, not supervised.
The CMO must also have visible authority within the organization. When your CMO makes a decision about advisory board composition or publication strategy, the organization should know that decision stands. If you routinely override your CMO in front of others, or if medical affairs staff bypass the CMO to bring scientific questions directly to you, the delegation structure is broken.
Address these patterns explicitly and quickly. A medical affairs organization that runs around its CMO is not a high-performing organization. It is a fragile one.
Scientific Integrity as a Delegation Non-Negotiable
One area where pharma CEOs must maintain active personal engagement regardless of delegation structure is scientific integrity. This does not mean reviewing every publication or attending every advisory board. It means setting and publicly holding the standards that govern how your company uses scientific evidence.
Make your scientific integrity principles explicit. They should govern how the company handles negative trial results, how it responds to post-marketing safety signals, and how it engages with independent researchers who produce evidence that challenges the company’s narrative.
Your Chief Medical Officer implements these principles. But the principles themselves reflect CEO values and risk posture, and the organization needs to see that the CEO takes them seriously. An annual communication to the medical affairs organization, reinforcing these standards and acknowledging their importance, is a CEO-level act that delegation cannot replace.
According to Harvard Business Review’s analysis of pharmaceutical trust, companies that embed scientific integrity at the executive level outperform peers on stakeholder trust and long-term commercial performance. The CEO’s role in that is visible commitment, not operational involvement.
Managing the Medical Affairs and Commercial Tension
The structural tension between medical affairs and commercial is one of the most persistent governance challenges in pharmaceuticals. Medical affairs has scientific independence as a core value. Commercial has revenue targets. These two priorities are not always in easy alignment.
Your delegation structure needs to address this tension explicitly rather than hoping it resolves itself at the functional level. Establish a clear framework: medical affairs does not promote products, and commercial does not direct scientific exchange. Define the boundary in writing. Give both your CMO and your CCO authority to enforce it within their organizations.
When the boundary is genuinely contested and the two leaders cannot resolve it, it escalates to you. These escalations should be infrequent if the boundary is clear and both leaders understand it. If you find yourself resolving medical-commercial boundary disputes regularly, the problem is a structural one and your governance framework needs revision.
Pharma regulatory affairs faces a similar interface challenge with commercial, and the resolution structure follows the same logic: clear boundaries, functional authority to enforce them, and CEO escalation only when needed.
Talent and Scientific Leadership Development
One of the most important investments you can make in medical affairs delegation is developing the scientific leadership capacity of your team. MSL managers, publication leads, HEOR directors, and medical affairs regional heads are the people who make day-to-day delegation work. If they are scientifically strong but organizationally underdeveloped, your CMO will struggle to delegate to them and will end up doing more than the role requires.
Build a development program for medical affairs leaders. This might include management coaching, cross-functional rotations, or access to external scientific leadership development programs. The investment pays back in delegation depth: when your CMO can confidently delegate to their team, your own delegation structure becomes more stable.
The Quarterly Medical Affairs Review
Just as commercial operations requires a quarterly business review, medical affairs benefits from a structured quarterly review at the CEO level. Structure it to cover: MSL field performance and HCP engagement metrics, publication pipeline progress, key advisory board outcomes and scientific insights, pharmacovigilance summary, and HEOR evidence development progress.
Your CMO presents. You ask questions, identify strategic implications, and make decisions within your authority. The review should take 60 to 90 minutes and produce explicit follow-up actions. It keeps you genuinely informed about scientific affairs without pulling you into operational management.
Final Thought
Medical and scientific affairs is the scientific conscience of your pharmaceutical organization. It deserves a CEO who holds it to the highest standards while giving it the organizational independence to operate with credibility. That combination requires a clear delegation structure, a trusted CMO, and the discipline to distinguish CEO oversight from CEO involvement.
Build the structure. Trust your CMO. Stay connected to the science at the strategic level. Your medical affairs organization will be stronger for it, and so will the patients who depend on your company’s scientific integrity.
Related Reading
For further context, explore How Pharma CEOs Delegate Business Development and Licensing and How Pharma CEOs Delegate Clinical Trial Operations.